Chemistry:Senaparib
From HandWiki
Senaparib is a drug that is being evaluated to treat various forms of cancer.[1] It is a PARP inhibitor.[2] In January 2025, senaparib was approved for use in China for treatment of advanced epithelial high-grade ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.[3]
References
- ↑ "Senaparib - IMPACT Therapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800049191.
- ↑ "The discovery of a potent PARP1 inhibitor Senaparib". Molecular Cancer Therapeutics 24 (1): OF1–OF9. June 2024. doi:10.1158/1535-7163.MCT-23-0625. PMID 38920409.
- ↑ "Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer". January 17, 2025. https://www.onclive.com/view/senaparib-receives-nmpa-approval-as-first-line-maintenance-in-ovarian-cancer.
 |  |
